Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking.
Methods: This first national quality assurance initiative was a retrospective analysis of patients with r/mCC diagnosed between 2018 and 2022, who were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free (PFS) and overall survival (OS) were calculated using Kaplan-Meier analysis.
Results: A total of 503 eligible patients (median age 55 years) were analyzed for r/mCC. 276/503 patients (55%) received first-line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted antibody therapy with bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment (the remaining 6/503 patients received immunotherapy only). For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95% CI 11-14), 8.8 months (95% CI 7.1-11), and 3 months (95% CI 2.3-4.8), and OS was 25 months (95% CI 21-31), 17 months (95% CI 14-22), and 3.6 months (95% CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second-line (2L) therapy.
Conclusion: Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including antibody therapy according to national guidelines. Moreover, 22% at initial diagnosis and 38% of patients at PD were not treated with systemic therapy at all. This might reflect poor general performance status, patients' preference, and/or lack of effective therapies especially in 2L treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081097 | PMC |
| http://dx.doi.org/10.1055/a-2520-5736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel Classification and Surgical Treatment Strategies for Congenital Accessory Auricle With Tragus Malformation.
J Craniofac Surg
September 2025
Department of Auricular Reconstruction, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Congenital accessory auricle is a common aurcile malformation, often associated with tragus malformation, impacting the appearance and psychology of patients. To optimize surgical treatments for congenital accessory auricle with tragus malformation, this article proposes a novel classification and explores surgical strategies.
Methods: This retrospective study included 120 patients with congenital accessory auricle and tragus malformation who underwent surgery between December 2019 and June 2024.
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multi-site, Double-blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).
Ann Am Thorac Soc
September 2025
Brigham and Women's Hospital, Division of Sleep and Circadian Disorders, Boston, Massachusetts, United States.
Rationale: There are insufficient data to inform the management of central sleep apnea (CSA) in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Nocturnal oxygen therapy (NOT) has been postulated to benefit CSA patients with HFrEF, but has not been rigorously studied. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.
View Article and Find Full Text PDFPASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
J Clin Oncol
September 2025
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore, MD.
Purpose: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX; mFFX) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers.
Patients And Methods: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in or . The primary end point was progression-free survival (PFS) between arms with 0.
Frequency of recurrent injuries in the deciduous dentition and associated factors.
Braz Oral Res
September 2025
Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Child and Adolescent's Oral Health, Belo Horizonte, MG, Brazil.
Understanding recurrent injuries in the deciduous dentition and possible associated factors could help in the control and prevention of such episodes in children. The aim of the present study was to investigate the frequency of recurrent injuries in the deciduous dentition and associated factors. A retrospective cross-sectional study was conducted involving 517 children aged between six months and six years treated at the Clinic for Traumatic Dental Injuries in the Deciduous Dentition of the School of Dentistry of the Universidade Federal de Minas Gerais.
View Article and Find Full Text PDFUtility of GERAADA score for predicting long-term survival following surgical repair of aortic dissection.
Interdiscip Cardiovasc Thorac Surg
September 2025
Department of Biomedical and Clinical Sciences, Universitá degli Studi di Milano, Milan, Italy.
Objectives: We aimed to assess the long-term survival following surgical repair because of type A aortic dissection (ATAAD) and the correlation with the preoperative GERAADA-score value.
Methods: We enrolled patients who underwent emergent aortic surgery because of ATAAD from 2010 to 2022 from 9 hospitals. Follow-up information was obtained by matching the clinical patient data with a national administrative database.